Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRS003 vs Bevacizumab in Advanced Non-squamous NSCLC
NCT04416035Phase 3Unknown
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Start
- Aug 2020
- Primary completion
- Oct 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of RPH-001 in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Teruisi Pharmaceutical Inc.. Status: unknown.
02
Drugs
RPH-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04416035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04416035.